KDventures portfolio company Modus Therapeutics pauses enrollment in Phase 2a sevuparin trial after serious adverse event
Bitget2026/10/15 05:48- KDventures announced October 15, 2026, that 51%-owned Modus Therapeutics temporarily paused Part 2 enrollment in its Phase 2a sevuparin trial.
- The study targets chronic kidney disease with anemia; the pause followed a serious adverse event in a sevuparin-treated patient.
- The event was reported as a suspected unexpected serious adverse reaction; a causal link to sevuparin remains unestablished.
- The pause was voluntary, not regulator-ordered. No ongoing treatment required discontinuation.
- Proof-of-concept results are now expected in the first quarter of 2027, versus around year-end 2026, pending completion of the safety assessment.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Anthropic spends $3.4 billion to purchase gas-fired power equipment to supply electricity for data centers
In September, Anthropic directly acquired Caterpillar equipment orders worth 3.4 billion USD, securing 1.7 GW of gas generator units, marking the largest single purchase of power generation equipment in AI history. This move bypassed utility middlemen, capturing scarce capacity at prices set years ago with near-term delivery. It is part of Anthropic's plan to invest over 895 billion USD in computing infrastructure by 2045.
Why Nintendo Stock Is One to Watch Ahead of the Holiday Season
A wallet address sold 1.44 million TRX via SunSwap in exchange for 460,000 USDT.
Data: Whales have cumulatively withdrawn approximately 13.4 million USDT from a certain exchange.
Crypto prices
More
